Phosphodiesterase-5 inhibitors and rosacea : report of 10 casesIOANNIDES, D; LAZARIDOU, E; APALLA, Z et al.British journal of dermatology (1951). 2009, Vol 160, Num 3, pp 719-720, issn 0007-0963, 2 p.Article

Erectile dysfunction and heart failure : the role of phosphodiesterase type 5 inhibitorsAL-AMERI, H; KLONER, R. A.International journal of impotence research. 2009, Vol 21, Num 3, pp 149-157, issn 0955-9930, 9 p.Article

Alprostadil for the treatment of impotenceHANCHANALE, Vishwanath; EARDLEY, Ian.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 3, pp 421-428, issn 1465-6566, 8 p.Article

Combined use of phosphodiesterase-5 inhibitors and selective serotonin reuptake inhibitors for temporary ejaculation failure in couple undergoing assisted reproductive technologiesSHAOMING LU; YUERAN ZHAO; JINGMEI HU et al.Fertility and sterility. 2009, Vol 91, Num 5, pp 1806-1808, issn 0015-0282, 3 p.Article

Sudden Hearing Loss From PDE-5 Inhibitors: A Possible Cellular Stress EtiologyMADDOX, Patrick T; SAUNDERS, James; CHANDRASEKHAR, Sujana S et al.The Laryngoscope. 2009, Vol 119, Num 8, pp 1586-1589, issn 0023-852X, 4 p.Conference Paper

Is phosphodiesterase type 5 inhibitor use associated with condom breakage? CommentaryCROSBY, R; YARBER, W. L; SANDERS, S. A et al.Sexually transmitted infections. 2009, Vol 85, Num 5, pp 404-406, issn 1368-4973, 3 p.Article

Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitorsDRESSER, M. J; DESAI, D; GIDWANI, S et al.International journal of impotence research. 2006, Vol 18, Num 1, pp 104-110, issn 0955-9930, 7 p.Article

Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors : Focus on «-blocker interactionsKLONER, Robert A.The American journal of cardiology. 2005, Vol 96, Num 12B, pp 42M-46M, issn 0002-9149Conference Paper

Role of Growth Factors in Improved Skin Flap Viability Caused by Phosphodiesterase-5 InhibitorBANDERA, Bradley C; PHAM, Thach; HILL-PRYOR, Crystal et al.The American surgeon. 2010, Vol 76, Num 6, pp 614-617, issn 0003-1348, 4 p.Article

Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction : Phosphodiesterase 5 inhibitors : pharmacology and therapeutic perspectivesAVERSA, Antonio; BRUZZICHES, Roberto; PILI, Marcello et al.Current pharmaceutical design. 2006, Vol 12, Num 27, pp 3467-3484, issn 1381-6128, 18 p.Article

Sex and the heartSCHWARZ, E. R; RODRIGUEZ, J.International journal of impotence research. 2005, Vol 17, pp S4-S6, issn 0955-9930, SUP1Conference Paper

A multifaceted approach to maximize erectile function and vascular healthMELDRUM, David R; GAMBONE, Joseph C; MORRIS, Marge A et al.Fertility and sterility. 2010, Vol 94, Num 7, pp 2514-2520, issn 0015-0282, 7 p.Article

Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in miceDHIR, Ashish; KULKAMI, S. K.Progress in neuro-psychopharmacology & biological psychiatry. 2007, Vol 31, Num 4, pp 921-925, issn 0278-5846, 5 p.Article

The GAF-Tandem Domain of Phosphodiesterase 5 as a Potential Drug TargetSCHULTZ, Joachim E; DUNKERN, Torsten; GAWLITTA-GORKA, Elvira et al.Handbook of experimental pharmacology. 2011, Vol 204, pp 151-166, issn 0171-2004, 16 p.Article

Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertensionPATTERSON, Dean; MCLNNES, Gordon T; WEBSTER, John et al.British journal of clinical pharmacology. 2006, Vol 62, Num 3, pp 280-287, issn 0306-5251, 8 p.Article

Validation of an LC―ESI-MS/MS method for the quantitation of phosphodiesterase-5 inhibitors and their main metabolites in rat serum and brain tissue samplesUNCETA, Nora; ECHEAZARRA, Leire; MONTANA, Mario et al.Journal of pharmaceutical and biomedical analysis. 2012, Vol 70, pp 529-533, issn 0731-7085, 5 p.Article

Daily use of phosphodiesterase 5 inhibitors for erectile dysfunction and lower urinary tract symptomsPIMENTEL, H; WALD, M; NIEDERBERGER, C et al.International journal of impotence research. 2008, Vol 20, Num 2, pp 145-149, issn 0955-9930, 5 p.Article

Phosphodiesterase-5 Inhibitors: Future Perspectives : Phosphodieterase-5 Inhibitors and their Use in the Treatment of Urological ConditionsKONSTANTINOS, Giannitsas; PETROS, Perimenis.Current pharmaceutical design (Print). 2009, Vol 15, Num 30, pp 3540-3551, issn 1381-6128, 12 p.Article

Prophylaxis of Erectile Function After Radical Prostatectomy with Phosphodiesterase Type 5 Inhibitors : Phosphodieterase-5 Inhibitors and their Use in the Treatment of Urological ConditionsDEHO, F; GALLINA, A; SALONIA, A et al.Current pharmaceutical design (Print). 2009, Vol 15, Num 30, pp 3496-3501, issn 1381-6128, 6 p.Article

Oral tadalafil reduces intra-abdominal adhesion reformation in ratsSERDAR KUTUK, Mehmet; TUNCAY OZGUN, Mahmut; BATUKAN, Cem et al.Human reproduction (Oxford. Print). 2012, Vol 27, Num 3, pp 733-737, issn 0268-1161, 5 p.Article

Isolation and structure elucidation of an interaction product of aminotadalafil found in an illegal health food productHÄBERLI, Adrian; GIRARD, Philippe; LOW, Min-Yong et al.Journal of pharmaceutical and biomedical analysis. 2010, Vol 53, Num 1, pp 24-28, issn 0731-7085, 5 p.Article

Erectile Dysfunction and Cardiovascular Disease : Efficacy and Safety of Phosphodiesterase Type 5 Inhibitors in Men With Both ConditionsNEHRA, Ajay.Mayo Clinic proceedings. 2009, Vol 84, Num 2, pp 139-148, issn 0025-6196, 10 p.Article

Lifestyle and metabolic approaches to maximizing erectile and vascular healthMELDRUM, D. R; GAMBONE, J. C; MORRIS, M. A et al.International journal of impotence research. 2012, Vol 24, Num 2, pp 61-68, issn 0955-9930, 8 p.Article

Effects of phosphodiesterase type 5 inhibitors on endothelial function and cardiovascular autonomic nerve function in menSTIRBAN, Alin; TAMLER, Ronald; ANDREI VERESIU, Loan et al.Journal of men's health (Print). 2011, Vol 8, Num 2, pp 109-118, issn 1875-6867, 10 p.Article

How to optimise treatment of erectile dysfunction above and beyond the beneficial effects of a phosphodiesterase type 5 inhibitorGOOREN, Louis.Journal of men's health. 2008, Vol 5, Num 2, pp 163-170, 8 p.Article